Sagimet Biosciences has dosed the first patient in its AURORA Phase 3 clinical trial in the U.S. to test denifanstat, an oral drug for moderate to severe acne. The trial aims to enroll about 800 patients, including 450 adolescents, and will evaluate the drug's safety and efficacy over 12 weeks with a 40-week extension. If approved, denifanstat could become the first new oral acne treatment approved by the FDA in over 40 years, addressing a significant need for the 10 million Americans with moderate to severe acne. Topline results are expected in the second half of 2027.
Sagimet Biosciences' clinical trial progress is noted here with Health-sector market data for context. For readers following Health-sector stocks, 68 out of 150 US stocks rose while 75 fell. Notable movers include RXRX at USD 3.51 with 0% Sell / 100% Buy order activity, NUWE at USD 0.54 up 3.34%, and MEDP at USD 642.01 down 3.09%. This data is as of Oct 22, 2026 18:01 WIB.
Scotiabank analyst Nat Schindler set a $650 price target for Meta Platforms, about 6.8% below its then-current price of $697.52. Despite Meta's strong revenue from Facebook, Instagram, and WhatsApp, investor concerns over increased artificial intelli...
UBS maintains a Buy rating on Berkshire Hathaway's Class A shares, currently trading near $811,320. The company's diverse portfolio and substantial cash reserves of about $360 billion provide stability and investment flexibility. Investor confidence ...
Barclays PLC reported Q3 2026 earnings with EPS of $0.66 and revenue of $9.86 billion, both slightly below analyst estimates. Pre-tax profit rose 12% year-over-year to £2.32 billion but missed forecasts due to a 19% decline in fixed-income revenue, p...
Comfort Systems USA is set to report strong Q3 2026 results, with analysts predicting earnings of $12.85 per share and revenue around $3.40 billion, driven by high demand in data centers and a record $14.06 billion backlog. The company showed robust ...
Karman has enabled NexGen Cloud to increase AI compute capacity by 60% within the same power budget at its Montreal data center by using its AI-driven power orchestration platform. This technology allows 16 NVIDIA B300 servers to run within the power...
